Edgewise Therapeutics

About Edgewise Therapeutics

Edgewise Therapeutics is a company focused on developing novel therapeutics for serious skeletal and cardiac muscle diseases. Their mission is to improve the lives of patients and families suffering from these conditions by leveraging unique expertise in muscle science, with a strong commitment to patients, determination, and integrity.

Products & Services

Sevasemten:An orally administered first-in-class fast skeletal myosin inhibitor for Becker, Duchenne, and other muscular dystrophies.

EDG-7500:A novel oral, selective cardiac sarcomere modulator for hypertrophic cardiomyopathy.

Specialties

Muscle Science Skeletal Muscle Diseases Cardiac Muscle Diseases Hypertrophic Cardiomyopathy Muscular Dystrophy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Offering T: - FT: Equity Offering	A: 200000000 MR: - FA: $200 million FAN: 200000000	D: 2025-04-02 FD: 2025-04-02	11 investors
2	RT: Equity Financing T: - FT: Equity Financing	A: 240000000 MR: - FA: 240 million FAN: 240000000	D: 2024-01-19 FD: 2024-01-19	11 investors

Equity Offering Latest

2025-04-02

$200.0M

11 investors (Pro only)

Equity Financing 2024-01-19

$240.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Kevin Koch

President, Chief Executive Officer and Director

A

Alan Russell

Co-Founder, Chief Scientific Officer and Director

R

Robert Blaustein

Chief Development Officer

R

R. Michael Carruthers

Chief Financial Officer

B

Behrad Derakhshan

Chief Operating Officer

J

Joanne M. Donovan

Chief Medical Officer

View 17 more team members with Pro

Unlock Full Team Directory

Recent News